Welcome to our dedicated page for Currenc Group Ordinary Shares news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group Ordinary Shares stock.
CURE PHARMACEUTICAL HOLDING COR (symbol: CURR), now known as Avenir Wellness Solutions, Inc., is at the forefront of innovative drug delivery and development. The company is dedicated to enhancing drug efficacy, safety, and the overall patient experience through its proprietary drug dosage forms and delivery systems. Avenir boasts an industry-leading full-service CGMP manufacturing facility and is renowned for its advanced oral thin film, Curefilm™, the most sophisticated oral thin film available today.
With a strong presence in the pharmaceutical cannabis sector and partnerships in the U.S., Canada, Israel, and Germany, Avenir is committed to improving how medicines are delivered and experienced worldwide. The company has developed a broad range of products using cutting-edge delivery platforms and collaborates with leading pharmaceutical companies.
Recently, Avenir has experienced significant growth, as evidenced by its financial performance. In the first quarter of 2023, the company reported a 15.1% increase in net revenue year-over-year and a 35.6% sequential increase from Q4 2022, reaching $1.2 million. Gross margins improved by 102 basis points to 78.9%, with further increases expected.
The company's strategic initiatives, including cost reductions and operating leverage, are expected to help narrow the net operating loss from continuing operations, excluding non-cash charges. Avenir's advertising and marketing campaigns, especially for its new product, DNA Complex, have garnered positive attention from prominent media outlets.
On August 9, 2023, the company officially changed its ticker symbol to AVRW and its corporate name to Avenir Wellness Solutions, reflecting its renewed focus on wellness technologies and high-margin products. The rebranding aligns with Avenir's long-term growth strategy to increase revenue through product development, strategic partnerships, and geographic licensing deals.
For more information, visit the company's website at avenirwellness.com.
CURE Pharmaceutical Holdings (OTC: CURR) announced that its OTF Vitamin D, branded as ImmunD3™ Nutri-Strips™, outperformed standard supplementation in achieving vitamin D sufficiency in pediatric patients undergoing stem cell therapy. Conducted at Cincinnati Children’s Hospital Medical Center (CCHMC), the study demonstrated significant improvements in vitamin D levels, enhancing patient outcomes and reducing complications. CCHMC aims to include this innovative supplement in its formulary, with plans for broader adoption in children’s hospitals nationwide.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that its subsidiary, Sera Labs, will launch the Seratopical Revolution skincare line in Walmart, CVS, and Bed Bath & Beyond stores. Additionally, the Nutri-Strips™ oral thin film, leveraging proprietary technology, will be available at CVS and Target.com. CEO Nancy Duitch emphasized the brand's competitive edge through advanced delivery systems and partnerships, including a collaboration with actress Nicole Kidman. The innovative skincare line combines plant-based ingredients with a unique delivery system for improved efficacy.
COFEPRIS, Mexico's FDA equivalent, has approved CURE Pharmaceutical's products for manufacture and sale in Mexico. This includes the innovative CUREform™ oral thin film (OTF) delivery system for various wellness products, such as CUREfilm Blue™ (sildenafil for erectile dysfunction), Vitamin D3, sugar-free electrolytes, and a melatonin sleep aid. CURE is in discussions with major distributors in Mexico and Latin America, aiming to expand its reach in the growing health and wellness market. This collaboration with Milagro Pharmaceuticals is expected to enhance CURE's production capabilities.
CURE Pharmaceutical Holdings (OTCQB: CURR) has announced a strategic partnership with Northern Response International to distribute the Seratopical Revolution® skin care line in Canada. This collaboration enables CURE to expand its market presence and brand portfolio internationally. The Seratopical line features plant-based formulations and a proprietary delivery system, endorsed by global icon Nicole Kidman. Northern Response will leverage its extensive distribution channels to promote this masstige brand, enhancing CURE’s reach in the lucrative beauty sector.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the upcoming issuance of U.S. Patent No. 11,179,331 for its product CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This innovative drug delivery method utilizes CURE's proprietary CUREfilm™ technology, enhancing patient experience with discreet and convenient administration. The erectile dysfunction drug market is projected to reach approximately USD$6.6 billion by 2025, with significant growth expected for sildenafil.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a remarkable 700% revenue increase to $2.1 million for Q2 2021, with gross profit rising 676% to $1.31 million. The net loss decreased significantly to $3.27 million from a loss of $13.47 million year-over-year. Key developments include CVS's upcoming launch of the Seratopical Revolution skincare line, ISO 9001 certification for its facility, successful initial clinical trials of CUREfilm Blue™, and a partnership with Biopharmaceutical Research Company to create cannabis-based medical products for Veterans.
CURE Pharmaceutical (OTC: CURR) announced that its skincare line, Seratopical Revolution, will be available at CVS starting Fall 2021. This partnership positions CURR for expansive market reach, targeting diverse customer needs with its innovative P3P complex, which enhances product efficacy without drying effects. CEO Nancy Duitch highlighted the brand's competitive edge through effective delivery systems and attractive packaging, alongside actress Nicole Kidman as a global ambassador. This development signifies an important milestone for CURR's growth strategy in the beauty industry.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that Chief Business Officer Jonathan Berlent will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17 at 7:00 a.m. EST. Berlent expressed pride in developing the company's psychedelic-based clinical pipeline, emphasizing the therapeutic potential of psychedelics for mental health disorders. The presentation will be accessible online for 90 days post-event. CURE is a leader in innovative drug delivery systems, operating from a state-of-the-art facility.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has launched Seratopical Revolution, a new line of anti-aging beauty products developed in collaboration with global brand ambassador Nicole Kidman. The product line features 11 plant-based items designed to hydrate and rejuvenate skin, utilizing a proprietary delivery system that enhances absorption. Products are made in the U.S. and are affordably priced. The line includes items such as Loving Hands Essential Oil and Indulgence Brown Sugar Scrub, aiming to merge nature and science for effective skincare.
CURE Pharmaceutical Holding Corp. (OTC: CURR) will hold a webcast on May 27, 2021, at 5 p.m. EDT for its investors. CEO Rob Davidson and Nancy Duitch, CEO of The Sera Labs, will discuss the company's future positioning and current achievements. Shareholders are encouraged to submit questions before the event. The company operates a 25,000 sq. ft. FDA-registered manufacturing facility and is known for its CUREform™ drug delivery platform, which enhances drug efficacy and safety.
FAQ
What is the current stock price of Currenc Group Ordinary Shares (CURR)?
What is the market cap of Currenc Group Ordinary Shares (CURR)?
What does Cure Pharmaceutical Holding Corp. do?
What is Curefilm™?
What are the financial highlights for the first quarter of 2023?
What recent changes has Avenir made to its corporate structure?
What is Avenir's mission?
How has Avenir's marketing strategy impacted their business?
What markets does Avenir operate in?
Who are Avenir's notable partners?
What is the significance of the name change to Avenir Wellness Solutions?
Where can I find more information about Avenir's financial performance?
